Helen J Lachmann

List of Publications by Citations

255 papers	17,035 citations	72 h-index	127 g-index
273 ext. papers	21,130 ext. citations	7 avg, IF	6.29 L-index

#	Paper	IF	Citations
255	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. *Circulation*, **2016**, 133, 2404-12	16.7	792
254	Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. *Arthritis and Rheumatism*, **2004**, 50, 607-12		650
253	Natural history and outcome in systemic AA amyloidosis. *New England Journal of Medicine*, **2007**, 356, 2361-71	59.2	640
252	Use of canakinumab in the cryopyrin-associated periodic syndrome. *New England Journal of Medicine*, **2009**, 360, 2416-25	59.2	613
251	Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. *New England Journal of Medicine*, **2003**, 348, 2583-4	59.2	580
250	Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. *New England Journal of Medicine*, **2002**, 346, 1786-91	59.2	516
249	Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. *Nature*, **2002**, 417, 254-9	50.4	412
248	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. *Circulation*, **2015**, 132, 1570-9	16.7	320
247	Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. *British Journal of Haematology*, **2003**, 122, 78-84	4.5	315
246	Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. *Arthritis and Rheumatism*, **2002**, 46, 2445-52		293
245	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. *Annals of the Rheumatic Diseases*, **2013**, 72, 678-85	2.4	292
244	T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells. *Science*, **2016**, 352, aad1210	33.3	268
243	Native T1 mapping in transthyretin amyloidosis. *JACC: Cardiovascular Imaging*, **2014**, 7, 157-65	8.4	265
242	T1 mapping and survival in systemic light-chain amyloidosis. *European Heart Journal*, **2015**, 36, 244-51	9.5	247
241	A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. *Blood*, **2015**, 126, 612-5	2.2	232
240	In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. *Journal of Experimental Medicine*, **2009**, 206, 1029-36	16.6	228
239	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. *New England Journal of Medicine*, **2018**, 378, 1908-1919	59.2	214

238	A new staging system for cardiac transthyretin amyloidosis. *European Heart Journal*, **2018**, 39, 2799-2806	9.5	211
237	Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. *Blood*, **2012**, 119, 4387-90	2.2	204
236	Senile systemic amyloidosis: clinical features at presentation and outcome. *Journal of the American Heart Association*, **2013**, 2, e000098	6	199
235	The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. *Journal of Allergy and Clinical Immunology: in Practice*, **2019**, 7, 1763-1770	5.4	196
234	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. *Nature Reviews Nephrology*, **2019**, 15, 45-59	14.9	189
233	Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. *Blood*, **2007**, 109, 457-64	2.2	183
232	CMR-based differentiation of AL and ATTR cardiac amyloidosis. *JACC: Cardiovascular Imaging*, **2014**, 7, 133-42	8.4	182
231	Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. *Journal of Clinical Investigation*, **2015**, 125, 4196-211	15.9	181
230	Recommendations for the management of autoinflammatory diseases. *Annals of the Rheumatic Diseases*, **2015**, 74, 1636-44	2.4	179
229	The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. *Annals of the Rheumatic Diseases*, **2014**, 73, 2160-7	2.4	179
228	The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. *Nature Reviews Nephrology*, **2011**, 8, 43-51	14.9	178
227	Eprodisate for the treatment of renal disease in AA amyloidosis. *New England Journal of Medicine*, **2007**, 356, 2349-60	59.2	177
226	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. *Annals of the Rheumatic Diseases*, **2015**, 74, 799-805	2.4	170
225	Systemic amyloidosis in England: an epidemiological study. *British Journal of Haematology*, **2013**, 161, 525-32	4.5	163
224	Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. *Human Mutation*, **2014**, 35, E2403-12	4.7	162
223	Somatic Mutations in and Severe Adult-Onset Autoinflammatory Disease. *New England Journal of Medicine*, **2020**, 383, 2628-2638	59.2	160
222	Classification criteria for autoinflammatory recurrent fevers. *Annals of the Rheumatic Diseases*, **2019**, 78, 1025-1032	2.4	159
221	Schnitzler's syndrome: diagnosis, treatment, and follow-up. *Allergy: European Journal of Allergy and Clinical Immunology*, **2013**, 68, 562-8	9.3	146

220	Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. *Annals of the Rheumatic Diseases*, **2011**, 70, 2095-102	2.4	146
219	Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. *Arthritis and Rheumatism*, **2003**, 48, 2632-44		143
218	Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. *Archives of Dermatology*, **2006**, 142, 1591-7		138
217	Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. *Annals of the Rheumatic Diseases*, **2015**, 74, 2043-9	2.4	135
216	Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. *European Heart Journal Cardiovascular Imaging*, **2014**, 15, 1289-98	4.1	131
215	Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 444-51	12.7	126
214	Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. *Circulation*, **2019**, 140, 16-26	16.7	124
213	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). *Annals of the Rheumatic Diseases*, **2017**, 76, 942-947	2.4	122
212	An international registry on autoinflammatory diseases: the Eurofever experience. *Annals of the Rheumatic Diseases*, **2012**, 71, 1177-82	2.4	121
211	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. *Annals of the Rheumatic Diseases*, **2015**, 74, 635-41	2.4	112
210	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. *Arthritis and Rheumatology*, **2016**, 68, 2795-2805	9.5	112
209	Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. *European Heart Journal*, **2012**, 33, 1120-7	9.5	111
208	Outcome in renal Al amyloidosis after chemotherapy. *Journal of Clinical Oncology*, **2011**, 29, 674-81	2.2	108
207	A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. *European Heart Journal*, **2015**, 36, 1098-105	9.5	102
206	Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. *Haematologica*, **2008**, 93, 295-8	6.6	102
205	Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. *Blood*, **2006** , 107, 1227-9	2.2	101
204	Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. *American Journal of Pathology*, **2011**, 179, 1978-87	5.8	100
203	Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. *Arthritis and Rheumatism*, **2002**, 46, 2571-3		100

202	Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. *Nephrology Dialysis Transplantation*, **2009**, 24, 676-8	4.3	99
201	Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. *European Heart Journal*, **2017**, 38, 1905-1908	9.5	92
200	Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. *Radiology*, **2015**, 277, 388-97	20.5	92
199	Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. *Arthritis Research and Therapy*, **2011**, 13, R202	5.7	91
198	Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. *British Journal of Haematology*, **2010**, 148, 760-7	4.5	89
197	Guidelines on the diagnosis and investigation of AL amyloidosis. *British Journal of Haematology*, **2015**, 168, 207-18	4.5	88
196	Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. *Annals of the Rheumatic Diseases*, **2014**, 73, 2168-73	2.4	87
195	Solid organ transplantation in AL amyloidosis. *American Journal of Transplantation*, **2010**, 10, 2124-31	8.7	87
194	Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. *Annals of the Rheumatic Diseases*, **2017**, 76, 173-178	2.4	81
193	A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. *Journal of Clinical Pathology*, **2015**, 68, 314-7	3.9	78
192	A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. *Blood*, **2019**, 134, 2271-2280	2.2	77
191	Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. *European Heart Journal Cardiovascular Imaging*, **2017**, 18, 1344-1350	4.1	76
190	Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. *Lancet Haematology,the*, **2015**, 2, e241-50	14.6	76
189	MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. *Annals of the Rheumatic Diseases*, **2014**, 73, 455-61	2.4	75
188	Guidelines on the management of AL amyloidosis. *British Journal of Haematology*, **2015**, 168, 186-206	4.5	73
187	A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. *Leukemia*, **2014**, 28, 2304-10	10.7	73
186	Systemic amyloidosis. *Current Opinion in Pharmacology*, **2006**, 6, 214-20	5.1	73
185	Natural history and outcome of light chain deposition disease. *Blood*, **2015**, 126, 2805-10	2.2	72

184	Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. *British Journal of Haematology*, **2006**, 134, 417-25	4.5	72
183	The emerging role of interleukin-1 in autoinflammatory diseases. *Arthritis and Rheumatism*, **2011**, 63, 314-24		70
182	AA amyloidosis complicating the hereditary periodic fever syndromes. *Arthritis and Rheumatism*, **2013**, 65, 1116-21		68
181	Improvement in renal cholesterol emboli syndrome after simvastatin. *Lancet, The*, **1998**, 351, 1331-2	40	68
180	Secondary, AA, Amyloidosis. *Rheumatic Disease Clinics of North America*, **2018**, 44, 585-603	2.4	68
179	Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism-UK Single Center Experience. *Frontiers in Immunology*, **2017**, 8, 1410	8.4	67
178	Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. *JACC: Cardiovascular Imaging*, **2020**, 13, 69-80	8.4	63
177	Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. *Annals of the Rheumatic Diseases*, **2018**, 77, 1558-1565	2.4	61
176	Organ transplantation in hereditary apolipoprotein AI amyloidosis. *American Journal of Transplantation*, **2006**, 6, 2342-7	8.7	61
175	AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. *Blood*, **2008**, 112, 4009-16	2.2	60
174	Neurologic manifestations of the cryopyrin-associated periodic syndrome. *Neurology*, **2010**, 74, 1267-70	6.5	59
173	Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance. *American Journal of Transplantation*, **2013**, 13, 433-41	8.7	58
172	Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. *Annals of the Rheumatic Diseases*, **2012**, 71, 2035-43	2.4	56
171	Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. *British Journal of Haematology*, **2002**, 117, 427-35	4.5	56
170	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. *Arthritis Care and Research*, **2017**, 69, 578-586	4.7	55
169	Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. *JACC: Cardiovascular Imaging*, **2019**, 12, 823-833	8.4	55
168	Development of the autoinflammatory disease damage index (ADDI). *Annals of the Rheumatic Diseases*, **2017**, 76, 821-830	2.4	54
167	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. *Rheumatology*, **2017**, 56, 2102-2108	3.9	54

166	Periodic fever syndromes. *Best Practice and Research in Clinical Rheumatology*, **2017**, 31, 596-609	5.3	54
165	A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. *Annals of the Rheumatic Diseases*, **2011**, 70, 309-14	2.4	54
164	CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. *JACC: Cardiovascular Imaging*, **2018**, 11, 152-154	8.4	52
163	Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 326, 230-239	27.4	51
162	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. *European Heart Journal*, **2020**, 41, 1439-1447	9.5	50
161	Hereditary lysozyme amyloidosis -- phenotypic heterogeneity and the role of solid organ transplantation. *Journal of Internal Medicine*, **2012**, 272, 36-44	10.8	48
160	Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. *Blood*, **2018**, 131, 974-981	2.2	47
159	Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis. *PLoS ONE*, **2017**, 12, e0181874	3.7	47
158	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. *Journal of Clinical Oncology*, **2016**, 34, 2037-45	2.2	46
157	Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. *Circulation Research*, **2014**, 114, 672-6	15.7	46
156	How not to miss autoinflammatory diseases masquerading as urticaria. *Allergy: European Journal of Allergy and Clinical Immunology*, **2012**, 67, 1465-74	9.3	45
155	Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. *Genes and Immunity*, **2004**, 5, 289-93	4.4	45
154	Amyloidosis and the lung. *Chronic Respiratory Disease*, **2006**, 3, 203-14	3	44
153	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. *Orphanet Journal of Rare Diseases*, **2017**, 12, 167	4.2	42
152	Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. *British Journal of Haematology*, **2014**, 166, 842-8	4.5	39
151	Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue-a case series and genetic exploration. *Rheumatology*, **2017**, 56, 209-213	3.9	38
150	Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature. *Arthritis Research and Therapy*, **2013**, 15, R30	5.7	38
149	Complement receptor CD46 co-stimulates optimal human CD8 T cell effector function via fatty acid metabolism. *Nature Communications*, **2018**, 9, 4186	17.4	38

148	Brief Report: whole-exome sequencing revealing somatic NLRP3 mosaicism in a patient with chronic infantile neurologic, cutaneous, articular syndrome. *Arthritis and Rheumatology*, **2014**, 66, 197-202	9.5	37
147	AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases. *Arthritis and Rheumatism*, **2006**, 54, 2010-4		37
146	Performance of Different Diagnostic Criteria for Familial Mediterranean Fever in Children with Periodic Fevers: Results from a Multicenter International Registry. *Journal of Rheumatology*, **2016**, 43, 154-60	4.1	36
145	Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 162-166	2.7	36
144	Brief Report: Association of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome With Gonosomal Mosaicism of a Novel 24-Nucleotide TNFRSF1A Deletion. *Arthritis and Rheumatology*, **2016**, 68, 2044-9	9.5	35
143	The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. *American Heart Journal*, **2012**, 164, 72-9	4.9	31
142	The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. *Journal of Pathology: Clinical Research*, **2019**, 5, 145-153	5.3	30
141	Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis. *Haematologica*, **2018**, 103, e165-e168	6.6	30
140	Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. *Rheumatology*, **2014**, 53, 665-70	3.9	29
139	Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. *British Journal of Haematology*, **2019**, 187, 638-641	4.5	28
138	Inflammatory bowel disease and systemic AA amyloidosis. *Digestive Diseases and Sciences*, **2013**, 58, 1689-97	4	28
137	The emerging role of interleukin-1 in autoinflammatory diseases. *Current Allergy and Asthma Reports*, **2011**, 11, 361-8	5.6	28
136	Systemic AA amyloidosis. *Sub-Cellular Biochemistry*, **2012**, 65, 541-64	5.5	27
135	IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis. *Journal of Investigative Dermatology*, **2020**, 140, 816-826.e3	4.3	27
134	Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. *Clinical and Experimental Rheumatology*, **2015**, 33, S46-53	2.2	27
133	Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis. *Haematologica*, **2011**, 96, 1079-80	6.6	26
132	Developments in the scientific and clinical understanding of autoinflammatory disorders. *Arthritis Research and Therapy*, **2009**, 11, 212	5.7	26
131	Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. *Annals of the Rheumatic Diseases*, **2017**, 76, 303-309	2.4	24

130	Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate. *Nature Communications*, **2020**, 11, 3412	17.4	24
129	A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. *Journal of Cardiology Cases*, **2011**, 4, e93-e97	0.6	24
128	Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger. *Arthritis and Rheumatology*, **2019**, 71, 1955-1963	9.5	23
127	Emerging treatments for amyloidosis. *Kidney International*, **2015**, 87, 516-26	9.9	20
126	Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. *British Journal of Haematology*, **2020**, 189, 643-649	4.5	20
125	Two types of amyloid in a single heart. *Blood*, **2014**, 124, 3025-7	2.2	20
124	A prospective study of nutritional status in immunoglobulin light chain amyloidosis. *Haematologica*, **2013**, 98, 136-40	6.6	19
123	Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. *Human Mutation*, **2019**, 40, 90-96	4.7	19
122	Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. *Turkish Journal of Medical Sciences*, **2020**, 50, 1591-1610	2.7	18
121	The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey. *Pediatric Rheumatology*, **2018**, 16, 19	3.5	18
120	ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the Next-Generation Sequencing Era. *Clinical Chemistry*, **2020**, 66, 525-536	5.5	17
119	In silico validation of the Autoinflammatory Disease Damage Index. *Annals of the Rheumatic Diseases*, **2018**, 77, 1599-1605	2.4	17
118	A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom. *British Journal of Haematology*, **2019**, 187, 642-652	4.5	17
117	Exploratory Study of MYD88 L265P, Rare NLRP3 Variants, and Clonal Hematopoiesis Prevalence in Patients With Schnitzler Syndrome. *Arthritis and Rheumatology*, **2019**, 71, 2121-2125	9.5	17
116	Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor. *Kidney International*, **2017**, 92, 1476-1483	9.9	17
115	Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2004**, 11, 44-9	2.7	17
114	Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein. *Kidney International Reports*, **2017**, 2, 461-469	4.1	16
113	Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis. *British Journal of Haematology*, **2018**, 182, 145-148	4.5	16

112	Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System. *Current Treatment Options in Neurology*, **2018**, 20, 43	4.4	16
111	Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation. *Nature Clinical Practice Cardiovascular Medicine*, **2009**, 6, 128-33		15
110	Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis. *British Journal of Haematology*, **2017**, 179, 575-585	4.5	14
109	Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine. *Blood*, **2018**, 132, 761-764	2.2	14
108	Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation. *Blood*, **2010**, 115, 4313; author reply 4314-5	2.2	13
107	Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis. *British Journal of Haematology*, **2018**, 183, 557-563	4.5	12
106	Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 189-193	2.7	12
105	Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis. *Haematologica*, **2015**, 100, 1469-76	6.6	12
104	Hypercalcemia in a patient with common variable immunodeficiency and renal granulomas. *American Journal of Kidney Diseases*, **2005**, 45, e90-3	7.4	12
103	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. *Journal of Rheumatology*, **2019**, 46, 429-436	4.1	12
102	Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis. *JACC: Cardiovascular Imaging*, **2021**,	8.4	12
101	Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting. *Haematologica*, **2014**, 99, e260-3	6.6	11
100	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. *Trials*, **2018**, 19, 465	2.8	11
99	Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis. *Nephrology Dialysis Transplantation*, **2018**, 33, 241-247	4.3	10
98	Autoinflammatory Syndromes in Children. *Indian Journal of Pediatrics*, **2016**, 83, 242-7	3	10
97	Familial Mediterranean fever caused by homozygous E148Q mutation complicated by Budd-Chiari syndrome and polyarteritis nodosa. *Rheumatology*, **2011**, 50, 624-6	3.9	10
96	Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis Results From the UK Amyloidosis Treatment Trial.. *Blood*, **2009**, 114, 2869-2869	2.2	10
95	Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. *ESC Heart Failure*, **2020**, 7, 3942	3.7	10

94	Renal amyloidosis. *British Journal of Hospital Medicine (London, England: 2005)*, **2010**, 71, 83-6	0.8	9
93	Autoinflammatory syndromes as causes of fever of unknown origin. *Clinical Medicine*, **2015**, 15, 295-8	1.9	8
92	Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.. *Blood*, **2006**, 108, 129-129	2.2	8
91	Renal transplant outcomes in amyloidosis. *Nephrology Dialysis Transplantation*, **2021**, 36, 355-365	4.3	8
90	Reply to: Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. Dinoia et al. *Clinical and Experimental Rheumatology*, **2017**, 35, 171	2.2	8
89	TRAP1 chaperone protein mutations and autoinflammation. *Life Science Alliance*, **2020**, 3,	5.8	7
88	Cardiac Magnetic Resonance-Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. *Circulation: Cardiovascular Imaging*, **2021**, CIRCIMAGING121012506	3.9	7
87	Comparison of Free Light Chain Assays: Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis. *American Journal of Clinical Pathology*, **2016**, 146, 78-85	1.9	7
86	How to prescribe a genetic test for the diagnosis of autoinflammatory diseases?. *Presse Medicale*, **2019**, 48, e49-e59	2.2	6
85	Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers. *British Journal of Haematology*, **2019**, 186, 460-470	4.5	6
84	Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria. *Haematologica*, **2020**, 105, 1405-1413	6.6	6
83	An unusual phenotype in Muckle-Wells syndrome associated with NLRP3 E311K. *Rheumatology*, **2011**, 50, 419-20	3.9	6
82	Novel pharmacological strategies in amyloidosis. *Nephron Clinical Practice*, **2003**, 94, c85-8		6
81	A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP.. *Blood*, **2009**, 114, 2796-2796	2.2	6
80	In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.. *Blood*, **2009**, 114, 745-745	2.2	6
79	99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 1304-1311	4.1	6
78	The value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosis. *European Journal of Haematology*, **2020**, 105, 352-356	3.8	5
77	Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2014**, 21, 276-81	2.7	5

76	Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature. *CEN Case Reports*, **2014**, 3, 68-74	1	5
75	Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis. *Journal of Cardiovascular Magnetic Resonance*, **2012**, 14,	6.9	5
74	Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis.. *Blood*, **2004**, 104, 755-755	2.2	5
73	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. *Trials*, **2020**, 21, 158	2.8	5
72	The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis. *Blood Cancer Journal*, **2020**, 10, 60	7	5
71	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. *JAMA Dermatology*, **2020**, 156, 1216-1222	5.1	5
70	INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 783-791.e4	5.4	5
69	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. *Rheumatology*, **2021**, 60, 3799-3808	3.9	5
68	One Hundred Cases of Localized Laryngeal Amyloidosis - Evidence for Future Management. *Laryngoscope*, **2021**, 131, E1912-E1917	3.6	5
67	Tocilizumab for the Treatment of Mevalonate Kinase Deficiency. *Case Reports in Pediatrics*, **2018**, 2018, 3514645	0.7	5
66	Carpal Tunnel Biopsy Identifying Transthyretin Amyloidosis. *Arthritis and Rheumatology*, **2017**, 69, 2051	9.5	4
65	Amyloidosis Diagnosed in Solid Organ Transplant Recipients. *Transplantation*, **2020**, 104, 415-420	1.8	4
64	ALchemy - A Large Prospective Real World' Study of Chemotherapy in AL Amyloidosis. *Blood*, **2011**, 118, 992-992	2.2	4
63	Autoinflammation: When is familial Mediterranean fever 'severe'?. *Nature Reviews Rheumatology*, **2016**, 12, 256-8	8.1	4
62	COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics. *Rheumatology Advances in Practice*, **2021**, 5, rkab043	1.1	4
61	High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. *Sleep Medicine*, **2017**, 32, 191-197	4.6	3
60	Two types of systemic amyloidosis in a single patient. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* , **2020**, 27, 275-276	2.7	3
59	Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 200-205	2.7	3

58	Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting as transfusion-dependent refractory haemophagocytosis. *Rheumatology*, **2018**, 57, 582-583	3.9	3
57	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. *Blood*, **2008**, 112, 1689-1689	2.2	3
56	Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment.. *Blood*, **2009**, 114, 1791-1791	2.2	3
55	Evidence of B Cell Clonality and Investigation Into Properties of the IgM in Patients With Schnitzler Syndrome. *Frontiers in Immunology*, **2020**, 11, 569006	8.4	3
54	Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. *Blood Cancer Journal*, **2021**, 11, 118	7	3
53	Trapped without a diagnosis: Tumour necrosis factor receptor-associated periodic syndrome (TRAPS). *Practical Neurology*, **2016**, 16, 304-7	2.4	3
52	Response to Letters Regarding Article, "Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis". *Circulation*, **2016**, 133, e450-1	16.7	3
51	Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 242-244	2.7	2
50	A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2015**, 22, 26-30	2.7	2
49	British kindred with dominant FMF associated with high incidence of AA amyloidosis caused by novel MEFV variant, and a review of the literature. *Rheumatology*, **2020**, 59, 554-558	3.9	2
48	Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome. *Pediatric Rheumatology*, **2019**, 17, 36	3.5	2
47	Muckle-Wells syndrome: a rare hereditary cryopyrin-associated periodic syndrome. *International Journal of Rheumatic Diseases*, **2017**, 20, 1873-1875	2.3	2
46	Standard Oral Melphalan Chemotherapy for AL Amyloidosis Revisited Using the Serum Free Light Chain Assay.. *Blood*, **2005**, 106, 3495-3495	2.2	2
45	Secondary, AA, Amyloidosis **2010**, 179-189		2
44	Cardiovascular disease risk assessment in patients with familial Mediterranean fever related renal amyloidosis. *Scientific Reports*, **2020**, 10, 18374	4.9	2
43	Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis. *British Journal of Haematology*, **2019**, 185, 977-980	4.5	2
42	Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK. *European Journal of Haematology*, **2021**, 106, 537-545	3.8	2
41	A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 72-73	2.7	1

40	A baffling case of severe systemic inflammation. Putting the pieces together: genes, environment and triggers. *Rheumatology*, **2017**, 56, 853-854	3.9	1
39	Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis. *British Journal of Haematology*, **2013**, 162, 856-8	4.5	1
38	Paraprotein-related renal disease and amyloid. *Medicine*, **2007**, 35, 512-515	0.6	1
37	The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. *Blood*, **2020**, 136, 40-40	2.2	1
36	The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis. *Blood*, **2020**, 136, 16-17	2.2	1
35	Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.. *Blood*, **2008**, 112, 1733-1733	2.2	1
34	A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.. *Blood*, **2012**, 120, 2966-2966	2.2	1
33	The Prognostic Significance of Phenotypically Normal Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma. *Blood*, **2014**, 124, 2073-2073	2.2	1
32	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. *Blood*, **2021**, 138, 2721-2721	2.2	1
31	Autoinflammatory Disorders **2017**, 393-435		1
30	Cholesterol metabolism drives regulatory B cell function		1
29	Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,. *Blood*, **2011**, 118, 3975-3975	2.2	1
28	Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. *Blood*, **2012**, 120, 4074-4074	2.2	1
27	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. *Heart*, **2021**,	5.1	1
26	Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data. *British Journal of Haematology*, **2021**, 194, 587-597	4.5	1
25	Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin light-chain (AL) amyloidosis. *British Journal of Haematology*, **2021**, 194, 1016-1023	4.5	1
24	The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre.. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2022**, 1-8	2.7	1
23	Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,. *Blood*, **2011**, 118, 3978-3978	2.2	0

22	The Authors Reply. *JACC: Cardiovascular Imaging*, **2020**, 13, 1294-1295	8.4	0
21	Successful treatment of systemic AA amyloidosis associated with underlying Hodgkin lymphoma. *British Journal of Haematology*, **2018**, 182, 619	4.5	0
20	Corticosteroid, Other Biologic and Small Molecule Therapies in Systemic Autoinflammatory Disorders **2019**, 775-791		
19	Paraprotein-related renal disease and amyloid. *Medicine*, **2015**, 43, 533-537	0.6	
18	Non-Hodgkin's lymphoma causing light-chain (AL) amyloidosis. *British Journal of Hospital Medicine (London, England: 2005)*, **2016**, 77, 188-9	0.8	
17	Paraprotein-related renal disease. *Medicine*, **2019**, 47, 666-671	0.6	
16	008 Demonstration of cardiac AL amyloidosis regression after succesful chemotherapy. a CMR study. *Heart*, **2017**, 103, A7.1-A7	5.1	
15	Long-Term Complications of Familial Mediterranean Fever. *Rare Diseases of the Immune System*, **2015**, 91-105	0.2	
14	The role of immunological assessment in patients with acute kidney injury and possible myeloma. *Advances in Chronic Kidney Disease*, **2012**, 19, 287-90	4.7	
13	Paraprotein-related renal disease and amyloid. *Medicine*, **2011**, 39, 481-485	0.6	
12	Impact of Chromosomal Abnormalities Revealed by Interphase FISH on Survival in Primary Light Chain Amyloidosis.. *Blood*, **2004**, 104, 4875-4875	2.2	
11	Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). *Rare Diseases of the Immune System*, **2020**, 235-245	0.2	
10	The UK Experience of Renal Transplantation in AL Amyloidosis. *Blood*, **2019**, 134, 2206-2206	2.2	
9	Amyloidosis and the Respiratory Tract **2015**, 91-111		
8	Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.. *Blood*, **2009**, 114, 2814-2814	2.2	
7	Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.. *Blood*, **2009**, 114, 1863-1863	2.2	
6	Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases. *Blood*, **2010**, 116, 3958-3958	2.2	
5	Treatment of Inflammasome-Related Disorders **2011**, 209-220		

4	Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.. *Blood*, **2012**, 120, 2978-2978	2.2
3	A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra. *Journal of Health Economics and Outcomes Research*, **2013**, 1, 123-133	1.6
2	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. *Efficacy and Mechanism Evaluation*, **2022**, 9, 1-106	1.7
1	Amyloidosis and the Kidney **2022**, 861-874	